Elo Mutual Pension Insurance Co Sells 272 Shares of Moderna, Inc. (NASDAQ:MRNA)

Elo Mutual Pension Insurance Co lowered its holdings in Moderna, Inc. (NASDAQ:MRNA) by 0.9% in the second quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 29,268 shares of the company’s stock after selling 272 shares during the period. Elo Mutual Pension Insurance Co’s holdings in Moderna were worth $3,476,000 at the end of the most recent quarter.

A number of other institutional investors have also recently bought and sold shares of the business. Cedar Wealth Management LLC boosted its holdings in Moderna by 45.0% in the 1st quarter. Cedar Wealth Management LLC now owns 290 shares of the company’s stock valued at $31,000 after purchasing an additional 90 shares during the period. Commerzbank Aktiengesellschaft FI boosted its holdings in Moderna by 1.7% in the 2nd quarter. Commerzbank Aktiengesellschaft FI now owns 5,550 shares of the company’s stock valued at $660,000 after purchasing an additional 93 shares during the period. CVA Family Office LLC boosted its holdings in Moderna by 21.6% in the 2nd quarter. CVA Family Office LLC now owns 541 shares of the company’s stock valued at $64,000 after purchasing an additional 96 shares during the period. Claro Advisors LLC raised its position in shares of Moderna by 2.0% in the 2nd quarter. Claro Advisors LLC now owns 5,546 shares of the company’s stock valued at $659,000 after buying an additional 108 shares in the last quarter. Finally, EverSource Wealth Advisors LLC raised its position in shares of Moderna by 32.3% in the 4th quarter. EverSource Wealth Advisors LLC now owns 475 shares of the company’s stock valued at $47,000 after buying an additional 116 shares in the last quarter. Institutional investors own 75.33% of the company’s stock.

Moderna Trading Down 3.0 %

MRNA opened at $69.86 on Thursday. Moderna, Inc. has a fifty-two week low of $62.55 and a fifty-two week high of $170.47. The company has a debt-to-equity ratio of 0.05, a current ratio of 4.09 and a quick ratio of 3.92. The firm has a market capitalization of $26.77 billion, a price-to-earnings ratio of -4.46 and a beta of 1.68. The company’s 50 day moving average price is $92.28 and its two-hundred day moving average price is $111.27.

Moderna (NASDAQ:MRNA) last posted its earnings results on Thursday, August 1st. The company reported ($3.33) earnings per share for the quarter, topping analysts’ consensus estimates of ($3.47) by $0.14. Moderna had a negative net margin of 116.18% and a negative return on equity of 21.35%. The firm had revenue of $241.00 million for the quarter, compared to analyst estimates of $128.41 million. During the same period in the previous year, the firm posted ($3.62) EPS. The company’s revenue for the quarter was down 29.9% compared to the same quarter last year. As a group, research analysts predict that Moderna, Inc. will post -9.52 earnings per share for the current year.

Insider Activity

In other news, Director Noubar Afeyan sold 15,000 shares of the company’s stock in a transaction on Wednesday, June 26th. The shares were sold at an average price of $127.22, for a total value of $1,908,300.00. Following the sale, the director now directly owns 2,284,015 shares of the company’s stock, valued at approximately $290,572,388.30. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. In related news, Director Noubar Afeyan sold 15,000 shares of the stock in a transaction on Wednesday, June 26th. The shares were sold at an average price of $127.22, for a total transaction of $1,908,300.00. Following the transaction, the director now directly owns 2,284,015 shares of the company’s stock, valued at $290,572,388.30. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, CFO James M. Mock sold 1,321 shares of the stock in a transaction on Wednesday, August 28th. The stock was sold at an average price of $79.39, for a total transaction of $104,874.19. Following the transaction, the chief financial officer now directly owns 8,600 shares in the company, valued at $682,754. The disclosure for this sale can be found here. In the last three months, insiders have sold 93,158 shares of company stock valued at $11,167,312. 15.70% of the stock is currently owned by insiders.

Analysts Set New Price Targets

Several equities analysts have recently commented on MRNA shares. Oppenheimer cut shares of Moderna from an “outperform” rating to a “market perform” rating in a research report on Friday, September 13th. The Goldman Sachs Group dropped their target price on shares of Moderna from $178.00 to $139.00 and set a “buy” rating for the company in a research report on Monday. Deutsche Bank Aktiengesellschaft upgraded shares of Moderna from a “sell” rating to a “hold” rating and dropped their target price for the company from $85.00 to $80.00 in a research report on Wednesday, August 7th. Evercore ISI restated an “in-line” rating and issued a $120.00 target price on shares of Moderna in a research report on Thursday, June 27th. Finally, JPMorgan Chase & Co. cut shares of Moderna from a “neutral” rating to an “underweight” rating and lowered their price objective for the stock from $88.00 to $70.00 in a research report on Friday, September 13th. Two equities research analysts have rated the stock with a sell rating, thirteen have given a hold rating and four have issued a buy rating to the stock. According to MarketBeat, the stock has an average rating of “Hold” and a consensus price target of $100.44.

Moderna Company Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.